Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
05 05 2023
Historique:
received: 24 02 2022
revised: 15 04 2022
accepted: 04 04 2023
medline: 1 5 2023
pubmed: 16 4 2023
entrez: 15 4 2023
Statut: ppublish

Résumé

A cluster-randomized trial of Vi-TT was conducted in Dhaka, Bangladesh, using JE vaccine as the control. A subset of 1,500 children were randomly selected on 2:1 basis (Vi-TT vs JE) to assess immune response. Blood was collected before vaccination, and on days 28, 545 and 730 post-vaccination and plasma anti-Vi-IgG response was measured. A robust, persistent antibody response was induced after single dose of Vi-TT, even after 2 years of vaccination. While there is no accepted serological antibody threshold of protection, analyzing the antibodies of children who received Vi-TT provides evidence that may later be useful in predicting population protection.

Identifiants

pubmed: 37061369
pii: S0264-410X(23)00397-3
doi: 10.1016/j.vaccine.2023.04.014
pii:
doi:

Substances chimiques

Tetanus Toxoid 0
Vaccines, Conjugate 0
Immunoglobulin G 0
Typhoid-Paratyphoid Vaccines 0
Antibodies, Bacterial 0

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3137-3140

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Farhana Khanam (F)

International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh; Menzies Health Institute Queensland and School of Pharmacy and Medical Science, Griffith University, Gold Coast, Australia.

Golap Babu (G)

International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.

Nazia Rahman (N)

International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.

Xinxue Liu (X)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.

Nazmul Hasan Rajib (NH)

International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.

Shams Uddin Ahmed (SU)

International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.

Md Ismail Hossen (MI)

International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.

Prasanta Kumar Biswas (PK)

International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.

Sarah Kelly (S)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.

Katherine Thesis-Nyland (K)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.

Yama Mujadidi (Y)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.

Nigel A J McMillan (NAJ)

Menzies Health Institute Queensland and School of Pharmacy and Medical Science, Griffith University, Gold Coast, Australia.

Andrew J Pollard (AJ)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.

John D Clemens (JD)

International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh; International Vaccine Institute, Seoul, Republic of Korea; UCLA Fielding, School of Public Health, Los Angeles, CA 90095-1772, USA.

Firdausi Qadri (F)

International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh. Electronic address: fqadri@icddrb.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH